OM:CAMXPharmaceuticals
Camurus (OM:CAMX) Is Up After Promising Phase 1b Obesity Data for Monthly Semaglutide - What's Next?
Camurus recently announced positive topline results from a Phase 1b study of its monthly FluidCrystal® semaglutide formulation, CAM2056, which showed substantial and dose-dependent reductions in body weight and glycemic markers in adults with overweight or obesity, with efficacy comparable to or exceeding that of weekly semaglutide.
This development is significant given the large global unmet need for chronic weight management solutions and the competitive landscape in GLP-1 therapies,...